Based on the Neurobo Pharmaceuticals Inc stock forecast from 0 analysts, the average analyst target price for Neurobo Pharmaceuticals Inc is not available over the next 12 months. Neurobo Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Neurobo Pharmaceuticals Inc is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Neurobo Pharmaceuticals Inc’s stock price was USD 1.62. Neurobo Pharmaceuticals Inc’s stock price has changed by -27.96% over the past week, -31.65% over the past month and -52.49% over the last year.
No recent analyst target price found for Neurobo Pharmaceuticals Inc
No recent average analyst rating found for Neurobo Pharmaceuticals Inc
Company Overview Neurobo Pharmaceuticals Inc
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts. Read Less
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combinat...Read More
Frequently Asked Questions About Neurobo Pharmaceuticals Inc (NRBO) Stock
Stock Target Advisor's fundamental analysis for Neurobo Pharmaceuticals Inc's stock is Bearish.
Unfortunately we do not have enough data on NRBO's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on NRBO's stock to indicate what its average analyst target is.
NRBO stock's Price/Earning ratio is 12.30.
Our analysis grades NRBO stock's Price / Earning ratio at F. This means that NRBO stock's Price/Earning ratio is above 60% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this NRBO may be a overvalued for its sector.
The last closing price of NRBO's stock was USD 1.62.
The most recent market capitalization for NRBO is USD 0.02B.
Unfortunately we do not have enough analyst data on NRBO's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Neurobo Pharmaceuticals Inc's stock.
As per our most recent records Neurobo Pharmaceuticals Inc has 8 Employees.
Neurobo Pharmaceuticals Inc's registered address is 545 Concord Avenue, Cambridge, MA, United States, 02138.
You can get more information about it from Neurobo Pharmaceuticals Inc's website at https://www.metaviatx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Neurobo Pharmaceuticals Inc (NRBO) Stock
Stock Target Advisor's fundamental analysis for Neurobo Pharmaceuticals Inc's stock is Bearish.
Unfortunately we do not have enough data on NRBO's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on NRBO's stock to indicate what its average analyst target is.
NRBO stock's Price/Earning ratio is 12.30.
Our analysis grades NRBO stock's Price / Earning ratio at F. This means that NRBO stock's Price/Earning ratio is above 60% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this NRBO may be a overvalued for its sector.
The last closing price of NRBO's stock was USD 1.62.
The most recent market capitalization for NRBO is USD 0.02B.
Unfortunately we do not have enough analyst data on NRBO's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Neurobo Pharmaceuticals Inc's stock.
As per our most recent records Neurobo Pharmaceuticals Inc has 8 Employees.
Neurobo Pharmaceuticals Inc's registered address is 545 Concord Avenue, Cambridge, MA, United States, 02138.
You can get more information about it from Neurobo Pharmaceuticals Inc's website at https://www.metaviatx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for NRBO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
